Northwest Biotherapeutics (NWBO) Depreciation & Amortization (CF) (2010 - 2026)

Northwest Biotherapeutics' Depreciation & Amortization (CF) history runs 17 years deep, the most recent figure standing at $771000.0 for Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) rose 77.65% year-over-year to $771000.0; the TTM figure through Mar 2026 stood at $2.4 million (up 37.2% YoY), while the FY2025 annual figure was $2.1 million, up 18.35% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $771000.0, up from $728000.0 in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $771000.0 in Q1 2026, with the low at $100000.0 in Q1 2022.
• The 5-year median for Depreciation & Amortization (CF) is $434000.0 (2024), against an average of $432705.9.
• The sharpest annual moves came in 2022 and 2023: Depreciation & Amortization (CF) soared 580.52% in 2022, then plunged 33.21% in 2023.
• Northwest Biotherapeutics' Depreciation & Amortization (CF) stood at $318000.0 in 2022, then jumped by 33.33% to $424000.0 in 2023, then advanced by 3.07% to $437000.0 in 2024, then soared by 66.59% to $728000.0 in 2025, then increased by 5.91% to $771000.0 in 2026.
• Business Quant data shows NWBO's Depreciation & Amortization (CF) at $771000.0 in Q1 2026, $728000.0 in Q4 2025, and $451000.0 in Q3 2025.